Efficacy Analysis of THP-containing Regimens As Neoadjuvant and Adjuvant Chemotherapy for Primary Breast Cancer

Li-Ze Wang,Tao Ouyang,Tian-Feng Wang,Yun-Tao Xie,Zhao-Qing Fan,Tie Fan,Ben-Yao Lin,Jin-Feng Li

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2012.02.014

2012-01-01

Abstract:Objective To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer. Methods Two hundred and eighty-nine primary breast cancer patients who were to be operated,two to eight cycles of pirarubicin in association with cyclophosphamide and 5-Fu ( CTF or CTFci regimen) were given before operation.The pathological response rate,effect and its relation with the infusion routes of 5-Fu were analyzed.Results The overall pathological complete remission (pCR) rate was 28.4％.The median follow-up period was 39 months.The 5-year DFS was 87.6％ (95％ CI:82.1％ to 92.7％ ),5-year DDFS was 89.9％ (95％ CI:84.0％ to 95.8％ ),and overall survival was 99.6％.CTFci (5-Fu,continuous infusion) regimen was superior to CTF regimen in pCR rates (32.3％ vs.20.2％,P =0.037 ),and 5-year DDFS were 92.9％ and 80.1％,respectively ( P =0.015).The pCR group was superior to non-pCR group in 5-year DDFS (92.4％ vs.85.6％,P =0.033 ).The pCR rate of patients with ER/PR-positive tumor was significantly lower than those of ER/PR-negative ( P =0.004).The 5-year DDFS rates of HER-2 (+) and HER-2(-) groups were 75.0％ and 91.9％,respectively (P=0.043).In the ER/PR-positve group,the 5-year DDFS of CTFci regimen was superior to those of CTF regimen,91.4％ vs.81.4％ (P =0.047).Conclusions CTF/CTFci regimen as neoadjuvant and adjuvant chemotherapy is effective for primary breast cancer.CTFci regimen is superior to CTF regimen in pathological complete response rate and 5-year DDFS.CTFci regimen may do better to ER/PR ( + ) patients' benefits compared with CTF regimen.